PY2302301A - Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas - Google Patents
Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismasInfo
- Publication number
- PY2302301A PY2302301A PY202302302301A PY2302301A PY2302301A PY 2302301 A PY2302301 A PY 2302301A PY 202302302301 A PY202302302301 A PY 202302302301A PY 2302301 A PY2302301 A PY 2302301A PY 2302301 A PY2302301 A PY 2302301A
- Authority
- PY
- Paraguay
- Prior art keywords
- helicase
- crystalline forms
- solid crystalline
- preparation process
- primase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22151820 | 2022-01-17 | ||
| EP22170332 | 2022-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PY2302301A true PY2302301A (es) | 2023-10-31 |
Family
ID=84982261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PY202302302301A PY2302301A (es) | 2022-01-17 | 2023-01-16 | Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250115565A1 (enExample) |
| EP (1) | EP4466255A1 (enExample) |
| JP (1) | JP2025502300A (enExample) |
| KR (1) | KR20240134979A (enExample) |
| AU (1) | AU2023206628A1 (enExample) |
| CA (1) | CA3246779A1 (enExample) |
| CL (1) | CL2024002124A1 (enExample) |
| IL (1) | IL314188A (enExample) |
| MX (1) | MX2024008821A (enExample) |
| PY (1) | PY2302301A (enExample) |
| TW (1) | TW202337444A (enExample) |
| UY (1) | UY40111A (enExample) |
| WO (1) | WO2023135303A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3265860A1 (en) * | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Pharmaceutical compositions against the herpes virus |
| CN121532378A (zh) | 2023-07-17 | 2026-02-13 | 创新分子股份有限公司 | 抗病毒解旋酶-引发酶抑制剂化合物的微粉化结晶盐酸盐 |
| WO2026078039A1 (en) | 2024-10-09 | 2026-04-16 | Innovative Molecules Gmbh | Oral administration forms of antiviral helicase-primase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10131128A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| GEP20207128B (en) | 2016-04-06 | 2020-07-10 | Molecules Gm Innovative | Aminothiazole derivatives useful as antiviral agents |
| DK3692039T3 (da) | 2017-10-05 | 2023-03-13 | Innovative Molecules Gmbh | Enantiomerer af substituerede thiazoler som antivirale forbindelser |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| MX2023004955A (es) | 2020-10-29 | 2023-05-17 | Innovative Molecules Gmbh | Compuestos de aminotiazol deuterados como compuestos antiviricos. |
-
2023
- 2023-01-16 IL IL314188A patent/IL314188A/en unknown
- 2023-01-16 KR KR1020247027250A patent/KR20240134979A/ko active Pending
- 2023-01-16 WO PCT/EP2023/050883 patent/WO2023135303A1/en not_active Ceased
- 2023-01-16 EP EP23700877.6A patent/EP4466255A1/en active Pending
- 2023-01-16 US US18/729,411 patent/US20250115565A1/en active Pending
- 2023-01-16 UY UY0001040111A patent/UY40111A/es unknown
- 2023-01-16 MX MX2024008821A patent/MX2024008821A/es unknown
- 2023-01-16 TW TW112101829A patent/TW202337444A/zh unknown
- 2023-01-16 PY PY202302302301A patent/PY2302301A/es unknown
- 2023-01-16 AU AU2023206628A patent/AU2023206628A1/en active Pending
- 2023-01-16 CA CA3246779A patent/CA3246779A1/en active Pending
- 2023-01-16 JP JP2024542125A patent/JP2025502300A/ja active Pending
-
2024
- 2024-07-15 CL CL2024002124A patent/CL2024002124A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024008821A (es) | 2024-07-29 |
| IL314188A (en) | 2024-09-01 |
| TW202337444A (zh) | 2023-10-01 |
| UY40111A (es) | 2023-08-15 |
| CA3246779A1 (en) | 2023-07-20 |
| JP2025502300A (ja) | 2025-01-24 |
| EP4466255A1 (en) | 2024-11-27 |
| US20250115565A1 (en) | 2025-04-10 |
| KR20240134979A (ko) | 2024-09-10 |
| CL2024002124A1 (es) | 2024-11-22 |
| WO2023135303A1 (en) | 2023-07-20 |
| AU2023206628A1 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40111A (es) | Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas | |
| CL2024001022A1 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| CL2024001964A1 (es) | Compuestos para la inhibición de nlrp3 y usos de estos | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| CO2019011873A2 (es) | Compuestos de heteroarilo bicíclicos 6–6 fusionados y su uso como inhibidores de lats | |
| MX2021015935A (es) | Formas de sal de acido bempedoico y metodos para utilizar el mismo. | |
| CL2018001484A1 (es) | Dinucleotidas de purino ciclico como moduladores de estimulador de genes de interferon (sting). | |
| NI200700138A (es) | Sal potasica de un inhibidor de la integrasa de vih | |
| HN2011000876A (es) | Inhibidores de las enzimas de proteina cinaza activadas por mitogeno p38 | |
| MX2024004119A (es) | Composiciones y metodos para el tratamiento de enfermedades de repeticion cag | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| UY39517A (es) | Inhibidores de la btk | |
| CO2023010694A2 (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
| CO2024013531A2 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| DOP2026000079A (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| CL2025000672A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer. | |
| CO2025003090A2 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| CL2022002259A1 (es) | Anticuerpos anti-axl y composiciones | |
| MX2026000476A (es) | Sales clorhidrato cristalinas micronizadas de compuestos inhibidores antiviricos de la helicasa-primasa | |
| CU24699B1 (es) | Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b | |
| CL2025000078A1 (es) | Formas sólidas de un derivado de triazina como modulador cbl-b | |
| MX2024002887A (es) | Metodos para tratar enfermedades neurodegenerativas. | |
| MX2024002886A (es) | Metodos para tratar enfermedades neurodegenerativas. | |
| MX2023010918A (es) | Metodos y composiciones para el tratamiento de enfermedades oculares. | |
| AR121013A1 (es) | Anticuerpos anti-cd40 y composiciones |